Commentary: Lessons from the COVID-19 global health response to inform TB case finding

Oga‐Omenka, Charity; Tseja-Akinrin, Azhee; Boffa, Jody; Heitkamp, Petra; Zarowsky, Christina

doi:10.1016/j.hjdsi.2020.100487

Cited by 11 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TB patients can experience the stigma against COVID-19, and it must be minimized because it would impact the success of TB treatment. 35 , 36 …”

Section: Discussionmentioning

confidence: 99%

“…7 Several guidelines to anticipate the impact of the COVID-19 pandemic on TB treatment have been established to mitigate the COVID-19 pandemic, including the sustainability of TB services and information on similarity, differences, and interactions between both diseases. [34][35][36][37] These documents are essential to tackle TB and COVID-19 at the same time. Several major concerns should be considered in controlling TB during the pandemic, such as administrative controls, environmental controls, and respiratory protection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia

Caren¹,

Iskandar²,

Pitaloka³

et al. 2022

JMDH

View full text Add to dashboard Cite

The current coronavirus disease 2019 (COVID-19) situation might deteriorate the efforts to eliminate tuberculosis (TB) in Indonesia. This study aimed to review the COVID-19 pandemic disruption on the management of TB treatment in Indonesia. We identified several disruptions due to the pandemic on TB control management. Firstly, there is a potential decrease in the funding for TB treatment. Financial disruptions caused by the COVID-19 pandemic have led to further setbacks. In many countries, including Indonesia, financial and other resources have been reallocated from TB to the COVID-19 response. Secondly, it has been highlighted that all TB services, including case detection and rapid diagnostic, have been disrupted by the pandemic. Thirdly, the pandemic would be associated with the lower quality of care and treatment for TB in Indonesia. It might decrease the enthusiasm of patients with TB, multi-drug resistant (MDR)-TB, and TB-human immunodeficiency virus (HIV) to visit TB hospitals because of social distancing measures by the government. Finally, the COVID-19 pandemic also has impacted critical activities of monitoring, evaluation, and surveillance. There are several lessons from other countries about managing TB treatment during the pandemic, such as combining screening for COVID-19 and TB by applying x-ray technology and artificial intelligence-based software. In addition, the use of telemedicine or telehealth in TB treatment is also beneficial to deliver medication, assess patients’ progress, and inform prevention strategies. To reach the target with the end TB strategy, the government of Indonesia can adopt the World Health Organization's (WHO’s) comprehensive strategies, such as integrated, patient-centered TB care and prevention strategies; bold policies and supportive systems; and intensified research and innovations.

show abstract

“…TB patients can experience the stigma against COVID-19, and it must be minimized because it would impact the success of TB treatment. 35 , 36 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia

Caren¹,

Iskandar²,

Pitaloka³

et al. 2022

JMDH

View full text Add to dashboard Cite

show abstract

“…To date, the COVID-19 response has demonstrated that, with political will, prioritization and investments, it is possible for the international community to mobilize resources, accelerate scientific discovery, and deploy new public health tools to fight a pandemic. 67 These same strategies can thus be employed for TB. However, the COVID-19 response, especially strict lock-downs and mobility restrictions, have also caused immense social and economic suffering and highlighted the need to strike a careful balance between immediate public health gains and unintended health and social side effects.…”

Section: Lessons Learned and Global Health Responsementioning

confidence: 99%

Different disease, same challenges: Social determinants of tuberculosis and COVID-19

Duarte¹,

Aguiar²,

Pinto³

et al. 2021

Pulmonology

View full text Add to dashboard Cite

Infectious diseases, such as tuberculosis (TB) and the novel coronavirus (COVID-19) relate to environmental factors, understanding of which is essential to inform policy and practice and tackle them effectively. The review follows the conceptual framework offered by the World Health Organization Commission on Social Determinants of Health (defined as “all those material, psychological and behavioural circumstances linked to health and generically indicated as risk factors’ in the conventional epidemiological language”). It describes the social factors behind TB and COVID-19, the commonalities between the two diseases, and what can be learned so far from the published best practices. The social determinants sustaining TB and COVID-19 underline the importance of prioritising health and allocating adequate financial and human resources to achieve universal health coverage and health-related social protection while addressing the needs of vulnerable populations. Rapid and effective measures against poverty and other major social determinants and sources of inequality are urgently needed to develop better health in the post-COVID-19 world.

show abstract

“…At a time of unprecedented political commitment to find, test and treat TB patients, evidence for strategies such as TB screening to inform in-country decision making globally, is vital. Further, the reversal in TB control efforts and case-detection due to the COVID-19 pandemic [47,48] may going forward, make TB screening even more important.…”

Section: Discussionmentioning

confidence: 99%

Does tuberculosis screening improve individual outcomes? A systematic review

et al. 2021

View full text Add to dashboard Cite

Background: To determine if tuberculosis (TB) screening improves patient outcomes, we conducted two systematic reviews to investigate the effect of TB screening on diagnosis, treatment outcomes, deaths (clinical review assessing 23 outcome indicators); and patient costs (economic review). Methods: Pubmed, EMBASE, Scopus and the Cochrane Library were searched between 1/1/1980-13/4/2020 (clinical review) and 1/1/2010-14/8/2020 (economic review). As studies were heterogeneous, data synthesis was narrative. Findings: Clinical review: of 27,270 articles, 18 (n=3 trials) were eligible. Nine involved general populations. Compared to passive case finding (PCF), studies showed lower smear grade (n=2/3) and time to diagnosis (n=2/3); higher pre-treatment losses to follow-up (screened 23% and 29% vs PCF 15% and 14%; n=2/2); and similar treatment success (range 68-81%; n=4) and case fatality (range 3-11%; n=5) in the screened group. Nine reported on risk groups. Compared to PCF, studies showed lower smear positivity among those cultureconfirmed (n=3/4) and time to diagnosis (n=2/2); and similar (range 80-90%; n=2/2) treatment success in the screened group. Case fatality was lower in n=2/3 observational studies; both reported on established screening programmes. A neonatal trial and post-hoc analysis of a household contacts trial found screening was associated with lower all-cause mortality. Economic review: From 2841 articles, six observational studies were eligible. Total costs (n=6) and catastrophic cost prevalence (n=4; range screened 9-45% vs PCF 12-61%) was lower among those screened. Interpretation: We found very limited patient outcome data. Collecting and reporting this data must be prioritised to inform policy and practice. Funding: WHO and EDCTP.

show abstract

Commentary: Lessons from the COVID-19 global health response to inform TB case finding

Cited by 11 publications

References 29 publications

COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia

COVID-19 Pandemic Disruption on the Management of Tuberculosis Treatment in Indonesia

Different disease, same challenges: Social determinants of tuberculosis and COVID-19

Does tuberculosis screening improve individual outcomes? A systematic review

Contact Info

Product

Resources

About